Q-omics provides the consensus-scored ASGR1 profile across patient tissues and cancer cell-line models. ASGR1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ASGR1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, ASGR1 RNA expression shows 15,537 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where ASGR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASGR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASGR1 survival associations across molecular data types. ASGR1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASGR1 RNA expression–survival associations across cancer types. High ASGR1 expression shows unfavorable associations in KIRC, ACC, UVM and UCS, but favorable associations in LGG and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ASGR1 RNA expression.
This table summarizes ASGR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ASGR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASGR1 shows lower tumor expression in LUAD, LUSC, THCA and CHOL and higher tumor expression in COAD and KIRC. The COAD box plot shows higher ASGR1 RNA expression in tumor versus normal tissue (log2 FC = +1.282, t-test p < 0.001).
This table shows molecular features associated with ASGR1 in patient tissues and cancer cell lines. In patient samples, ASGR1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ASGR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BONE.
